MEDIF
Price
$0.06
Change
-$0.00 (-0.00%)
Updated
Aug 27 closing price
Capitalization
22.81M
NPPNY
Price
$5.37
Change
+$0.03 (+0.56%)
Updated
Aug 7 closing price
Capitalization
1.41B
Interact to see
Advertisement

MEDIF vs NPPNY

Header iconMEDIF vs NPPNY Comparison
Open Charts MEDIF vs NPPNYBanner chart's image
Medipharm Labs
Price$0.06
Change-$0.00 (-0.00%)
Volume$101.03K
Capitalization22.81M
Nippon Shinyaku
Price$5.37
Change+$0.03 (+0.56%)
Volume$1.42K
Capitalization1.41B
MEDIF vs NPPNY Comparison Chart in %
Loading...
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NPPNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MEDIF vs. NPPNY commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEDIF is a Hold and NPPNY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (MEDIF: $0.06 vs. NPPNY: $5.37)
Brand notoriety: MEDIF and NPPNY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: MEDIF: 274% vs. NPPNY: 76%
Market capitalization -- MEDIF: $22.81M vs. NPPNY: $1.41B
MEDIF [@Pharmaceuticals: Generic] is valued at $22.81M. NPPNY’s [@Pharmaceuticals: Generic] market capitalization is $1.41B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MEDIF’s FA Score shows that 0 FA rating(s) are green whileNPPNY’s FA Score has 1 green FA rating(s).

  • MEDIF’s FA Score: 0 green, 5 red.
  • NPPNY’s FA Score: 1 green, 4 red.
According to our system of comparison, NPPNY is a better buy in the long-term than MEDIF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MEDIF’s TA Score shows that 3 TA indicator(s) are bullish while NPPNY’s TA Score has 5 bullish TA indicator(s).

  • MEDIF’s TA Score: 3 bullish, 7 bearish.
  • NPPNY’s TA Score: 5 bullish, 0 bearish.
According to our system of comparison, NPPNY is a better buy in the short-term than MEDIF.

Price Growth

MEDIF (@Pharmaceuticals: Generic) experienced а +4.18% price change this week, while NPPNY (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.61%. For the same industry, the average monthly price growth was +12.19%, and the average quarterly price growth was +85.29%.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.61% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NPPNY($1.41B) has a higher market cap than MEDIF($22.8M). MEDIF YTD gains are higher at: 34.867 vs. NPPNY (-19.127). NPPNY has higher annual earnings (EBITDA): 36.5B vs. MEDIF (-4.75M). NPPNY has more cash in the bank: 66B vs. MEDIF (8.44M). MEDIF has less debt than NPPNY: MEDIF (125K) vs NPPNY (2.55B). NPPNY has higher revenues than MEDIF: NPPNY (154B) vs MEDIF (43M).
MEDIFNPPNYMEDIF / NPPNY
Capitalization22.8M1.41B2%
EBITDA-4.75M36.5B-0%
Gain YTD34.867-19.127-182%
P/E RatioN/A6.55-
Revenue43M154B0%
Total Cash8.44M66B0%
Total Debt125K2.55B0%
FUNDAMENTALS RATINGS
MEDIF vs NPPNY: Fundamental Ratings
MEDIF
NPPNY
OUTLOOK RATING
1..100
7147
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
7
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9518
PRICE GROWTH RATING
1..100
4762
P/E GROWTH RATING
1..100
10079
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NPPNY's Valuation (7) in the null industry is significantly better than the same rating for MEDIF (91). This means that NPPNY’s stock grew significantly faster than MEDIF’s over the last 12 months.

NPPNY's Profit vs Risk Rating (100) in the null industry is in the same range as MEDIF (100). This means that NPPNY’s stock grew similarly to MEDIF’s over the last 12 months.

NPPNY's SMR Rating (18) in the null industry is significantly better than the same rating for MEDIF (95). This means that NPPNY’s stock grew significantly faster than MEDIF’s over the last 12 months.

MEDIF's Price Growth Rating (47) in the null industry is in the same range as NPPNY (62). This means that MEDIF’s stock grew similarly to NPPNY’s over the last 12 months.

NPPNY's P/E Growth Rating (79) in the null industry is in the same range as MEDIF (100). This means that NPPNY’s stock grew similarly to MEDIF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MEDIFNPPNY
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
37%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
26%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
30%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
29%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
25%
Advances
ODDS (%)
Bullish Trend 24 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 14 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NPPNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TKCOF62.01N/A
N/A
Toho Co., Ltd.
ALSSF2.89N/A
N/A
Alsea SA
CNDAU12.99N/A
N/A
Concord Acquisition Corp II
DRREF10.50N/A
N/A
Dream Residential Real Estate Investment Trust
BBUZ0.03N/A
-2.00%
Bebuzee Inc.

NPPNY and

Correlation & Price change

A.I.dvisor tells us that NPPNY and MEDIF have been poorly correlated (+11% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NPPNY and MEDIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NPPNY
1D Price
Change %
NPPNY100%
N/A
MEDIF - NPPNY
11%
Poorly correlated
-2.11%
OVATF - NPPNY
10%
Poorly correlated
N/A
OMID - NPPNY
3%
Poorly correlated
-22.81%
OILFF - NPPNY
-1%
Poorly correlated
+10.13%
MKGAF - NPPNY
-1%
Poorly correlated
+0.86%
More